Skip to main content

This suit was filed by Hyundai against car companies Mahindra and Renault who had collaborated to form a joint venture in India to launch a hatchback car under the brand SANDERO.

Owing to the similarity between the impugned mark SANDERO and Hyundai’s own famous hatchback SANTRO, Hyundai proceeded to file the suit in 2009 on a quia timet cause of action since the SANDERO car was not yet commercially available in the Indian market.

After Hyundai had led evidence in the suit, the Defendants informed the court that Mahindra and Renault’s joint venture in India had come to an end and they had withdrawn their application seeking registration of the SANDERO mark in India. They did not intend to launch the SANDERO car in India, at the time. However the Defendants were not willing to undertake that they would not launch the SANDERO car in India in future and the matter was kept pending.

The counsel for the parties continued to explore ways for their clients to arrive at a mutual settlement, even at the stage of final hearing, and eventually agreed that:

A The Defendants will tender an undertaking to Court that they will not launch the SANDERO car in India for at least the next 3 years.

B The Plaintiff will withdraw the suit on the basis of this undertaking with liberty to file a fresh suit should any cause of action arise against the Defendants in future.

C The Plaintiff will also be permitted to rely on the evidence led in the present suit in any future proceedings.

The Court accepted the terms of settlement proposed by the parties and recorded the Defendants undertaking. The Plaintiff was permitted to withdraw the suit with liberty to file afresh and rely on the evidence led, in future proceedings.

Hyundai Motor India Ltd. v Mahindra Renault Pvt. Ltd.; before Delhi High Court; order dated 12.10.2017

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
•
Oct 27, 2026

When a pharmaceutical company develops a new formulation of an existing drug, is it creating a genuine innovation or extending its monopoly over a medicine

Evergreening or Genuine Innovation? The Patentability of New Drug Formulations in India
News & Updates, Thought Leadership
•
Oct 23, 2026

Imagine a researcher using artificial intelligence to identify a new material, a pharmaceutical team using machine learning to discover a promising compound,

Can AI-Assisted Inventions Be Patented in India?
News & Updates, Thought Leadership
•
Oct 20, 2026

Every time someone publishes an article, uploads a photograph, releases a song or shares research online, they contribute to an expanding body of human

Who Owns Internet’s Knowledge? Copyright, AI Training and Indian Law
News & Updates, Thought Leadership
•
Oct 17, 2026

An active pharmaceutical ingredient (API) is the substance responsible for a medicine’s therapeutic effect. Developing one can involve years of chemical

API Process Patents in India: Key Patent Infringement Disputes and Court Decisions